B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes.
about
ZAP-70 in B cell malignanciesMutation pattern of paired immunoglobulin heavy and light variable domains in chronic lymphocytic leukemia B cellsEmerging drugs for chronic lymphocytic leukaemia.Analysis of VH gene sequences using two web-based immunogenetics resources gives different results, but the affinity maturation status of chronic lymphocytic leukaemia clones as assessed from either of the resulting data sets has no prognostic signiCellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities.A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display.Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells.High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival.HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses.MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells.Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior.Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemiaB-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia.Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemiaThe B lineage transcription factor E2A regulates apoptosis in chronic lymphocytic leukemia (CLL) cells.Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia.Biological and clinical heterogeneity of B-cell chronic lymphocytic leukemia.DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia.Serum thymidine kinase activity: analytical performance, age-related reference ranges and validation in chronic lymphocytic leukemiaIntraclonal cell expansion and selection driven by B cell receptor in chronic lymphocytic leukemia.Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL.TACI expression and signaling in chronic lymphocytic leukemiaAberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells.Progressive immunoglobulin gene mutations in chronic lymphocytic leukemia: evidence for antigen-driven intraclonal diversification.Similarities and differences between the light and heavy chain Ig variable region gene repertoires in chronic lymphocytic leukemia.CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study.CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemiaTLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells.CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell deathMechanisms of B-cell lymphoma pathogenesis.The immunoglobulin genes and chronic lymphocytic leukemia (CLL).Ongoing in vivo immunoglobulin class switch DNA recombination in chronic lymphocytic leukemia B cells.Chronic lymphocytic leukemia B cells can undergo somatic hypermutation and intraclonal immunoglobulin V(H)DJ(H) gene diversification.CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells.Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.CD39/NTPDase-1 activity and expression in normal leukocytesNonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3.CD38 and chronic lymphocytic leukemia: a decade later.FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.Hepatic manifestations in hematological disorders.
P2860
Q28279902-FE72F267-847D-4A38-B23E-79B5AB1EC551Q29048163-EE4B397D-255E-44F1-A2DC-697F4FE1C97CQ30353154-5F02F5AC-905D-402F-9828-401D0C6ED37CQ33212981-EB031B85-323B-43D5-9C06-0F4215E786F6Q33350258-B2557944-6CDF-4803-A28E-F8158119573DQ33492227-2965B881-611A-45A5-8F8A-02B2B8854B6EQ33494799-2FAAAA2A-5CB9-4FFC-9B4F-77C746A826C8Q33813862-34D97B81-8C0B-4C63-B778-74827BA96FE5Q33831931-2045475F-0E3F-479C-80FB-DC16556C86B4Q33847322-DFF41EF7-F9AE-4A98-B3D8-52C0E08A11B0Q34095636-37461C93-9BF1-457F-8A33-FB99B3782951Q34245048-59AFBE3B-8F19-42F1-92F9-153C9ADCB866Q34279007-80FF4785-C24C-4AC8-8309-5889C715F656Q34349298-E11C7C07-3092-41D4-AB68-AF6E77F286E8Q35011166-9FB55F88-DC74-40DE-86F8-ACEB45C527FEQ35011409-77DF97B5-2344-4C7D-979F-46BAA45B68F4Q35104372-34CCBD88-8D7C-4928-8E10-B8024643B1F5Q35116184-4977552D-7456-4288-A760-640DD5FFE75DQ35118658-6E2C92B0-BEA4-4799-8392-3F3D6B30FE9AQ35136742-20814452-4CCE-4FD1-8047-91A147242DA6Q35188629-6A5E34F6-2DD9-4D68-A5D6-43F53BFD87D6Q35534809-75EEEE38-D586-41A0-9376-3DEC99702603Q35611369-CCE739D3-1693-4DB7-BEBF-2766D0ED93FDQ35628846-7D93CA71-0391-4A77-8E91-1F289F2CD189Q35690880-A253DAB7-BE70-47E6-A72E-CEF274FD84D0Q35717883-DA7ED759-B768-42F0-95F7-F36A58A7E294Q35828073-59AA0A2E-BFD8-4B63-A5B3-87A4EAA7CE64Q35861964-26EDF8E4-5A08-4DEB-8F54-0F04AC2818C4Q35930211-A2B93071-C819-4549-A924-066A20FBBE85Q36085626-6A05C0DA-DD15-4AA5-9E0A-AE11DA570871Q36216608-3CD8DD96-DC15-49A3-9F95-ADBE96BEB61BQ36224328-AE4AAB1C-07EB-4DEB-AC27-0C578BDCE8F9Q36371091-C1084DCC-A488-4C5F-AE29-2AA232D4FBF4Q36384860-7EE2ECD5-F863-4D80-AE36-75E87137943EQ36460314-B10D9FBD-7063-4B6C-83DA-81FF97B1116CQ36479951-3CC10948-9514-4C14-8A78-17C93DA5E9F1Q36491858-21447259-1410-40A3-8088-6C6F10C0560AQ36615126-42EFED89-7C84-4EA9-848A-4EE0F67E2CF2Q36732806-7E2C2A32-AC49-4EA3-89BB-85F76C53FB89Q36765838-D263E280-BFEA-46BC-846D-03551CB99F66
P2860
B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
B-cell chronic lymphocytic leu ...... gen-experienced B lymphocytes.
@ast
B-cell chronic lymphocytic leu ...... gen-experienced B lymphocytes.
@en
B-cell chronic lymphocytic leu ...... gen-experienced B lymphocytes.
@nl
type
label
B-cell chronic lymphocytic leu ...... gen-experienced B lymphocytes.
@ast
B-cell chronic lymphocytic leu ...... gen-experienced B lymphocytes.
@en
B-cell chronic lymphocytic leu ...... gen-experienced B lymphocytes.
@nl
prefLabel
B-cell chronic lymphocytic leu ...... gen-experienced B lymphocytes.
@ast
B-cell chronic lymphocytic leu ...... gen-experienced B lymphocytes.
@en
B-cell chronic lymphocytic leu ...... gen-experienced B lymphocytes.
@nl
P2093
P1433
P1476
B-cell chronic lymphocytic leu ...... gen-experienced B lymphocytes.
@en
P2093
Angelo Valetto
Cristina P Sison
Emilia Albesiano
Fabio Ghiotto
Franco Fais
Jonathan Kolitz
Jurgen Frey
Kanti R Rai
Manlio Ferrarini
Nicholas Chiorazzi
P304
P356
10.1182/BLOOD.V99.11.4087
P407
P577
2002-06-01T00:00:00Z